Advanced Filters
noise
Found 842 clinical trials
M Madeleine Hackney, MD

Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease

Interventions that affect many different aspects of human ability rather than just one aspect of human health are more likely to be successful in preventing and treating Alzheimer's disease (AD). Functional decline in AD is severely impacted by impaired ability to do physical actions while having to make decisions and …

50 - 80 years of age All Phase N/A
S Susan Racette, Ph.D.

Time Restricted Eating in Alzheimer's Disease (TREAD)

This pilot and feasibility study will enable the research team to determine the feasibility of implementing a time-restricted eating regimen among adults with mild cognitive impairment (MCI) and the impact of time-restricted eating on cognitive performance and biomarkers of metabolic health in this population. Study staff will execute the specific …

60 - 80 years of age All Phase N/A
D DUMURGIER Julien, MD, PhD

Donepezil Versus Non-drug Treatment in Alzheimer's Disease.

Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency. French health authorities currently preconize a non-rug approach based on cognitive remediation or stimulation. The aim of this study is to compare …

50 years of age All Phase 3
J Jessica St. Romain, MA

Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"

The RAATE proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. There are three main objectives of the protocol: to determine if a physical activity …

60 years of age All Phase N/A
C Craig Ritchie, Professor, MD, PhD

A Study to Assess THN391 in Subjects With Alzheimer's Disease

This is a Phase 1b study to evaluate different doses of the drug and see whether a drug is safe and how it behaves in the body. THN391 has already been assessed in healthy people without Alzheimer's disease. This is the first study of THN391 in patients with Early Alzheimer's …

65 - 85 years of age All Phase 1

The Wandering Nerve: Gateway to Boost Alzheimer's Disease Related Cognitive Performance

In this research study the investigators want to find out if a non-invasive electrical brain stimulation method called RAVANS (also called tVNS) can have a beneficial effect on cognition in older individuals. The investigators also want to understand whether certain individual factors contribute to the effect of RAVANS on cognition. …

60 - 85 years of age All Phase N/A
B Brent Mausbach, PhD

A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers

This is a randomized controlled trial over 5 years, using Stage II of the NIH-defined stage model for behavioral intervention development. We will evaluate the efficacy of the sleep intervention program (Care2Sleep) on sleep, health status measures, and quality of life (for dyads), and inflammation (for caregivers only). Eligible participants …

18 years of age All Phase N/A

Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?

Alzheimer's disease (AD) is characterised by a progressive loss of memory and cognitive function. In the early stages of AD, there is a progressive accumulation of molecules: β-amyloid peptides (Aβ) in the brain. There is a link between the accumulation of Aβ peptides and the deterioration of sleep, but current …

50 - 85 years of age All Phase N/A

MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease

Patients with Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD) may or may not develop Alzheimer's disease (AD) dementia. Yet identifying patients at risk is crucial: delaying the onset of the disease by 5 years could reduce prevalence by 50%. To achieve this, we need affordable biomarkers combined with …

50 - 80 years of age All Phase N/A
M Maria Stefania De Simone, Dr

REducing the Risk of COgnitive DEcline ad Dementia in Patients With Subjective Cognitive Decline Through an Immersive Virtual Reality and Telemedicine-based Multi-component Intervention: the SCD-ReCODED Study

Older adults with subjective cognitive decline (SCD) are at high risk of developing dementia and frequently experience subclinical symptoms (e.g., anxiety, depression) which are themselves associated with dementia and cognitive decline risk. To date, the lack of effective disease-modifying treatments, along with the reliable identification of modifiable lifestyle risk factors …

55 - 80 years of age All Phase N/A

Simplify language using AI